Change has never been the word most associated with pharma. Irrespective of a record-breaking number of newly approved drugs over the last two years, a new report just out warns that continued growth is not sustainable unless R&D efficacies at drug companies are addressed and new paradigms adopted.
Change has never been the word most associated with pharma. Irrespective of a record-breaking number of newly approved drugs over the last two years, a new report just out warns that continued growth is not sustainable unless R&D efficacies at drug companies are addressed and new paradigms adopted.
As clinical trials continue to improve their operational efficiencies, R&D must keep pace to move forward with their prodigious output of new products and to insure commercial success, says Kenneth Kaitin, director of the US Tufts Center for the Study of Drug Development (Tufts CSDD), which produced the study, Tufts CSDD Outlook 2014.
To give you an idea of just how slow pharma moves, Kaitin pointed out that the drug development model has not fundamentally changed since 1962, when U.S. Senator Estes Kefauver and Representative Oren Harris’s Drug Efficacy Amendment established the current standard for clinical testing of investigational drugs in the U.S.
Chances are the name Estes Kefauver is not familiar to the majority of people reading this blog. But in his day, Senator Kefauver was a mover and shaker in the power corridors of the nation’s capital. Beloved by progressive Democrats, he was also famous for wearing his trademark coonskin cap, which prompted the Davy Crockett craze of the 1950′s (I had one).
To move forward from the past and to be in sync with today’s clinical design improvements and pharma’s new, progressive partnership models “will depend on the development of industry best practices, which will enable companies to maximize their formidable R&D investment and help ensure future commercial success,” suggests Kaitin.
Kaitin also pointed out the other highlights from the outlook for the coming year, including:
• A growing concern over expensive, late-stage clinical development failures will lead firms to reassess their use of meta-analyses and subgroup analysis and make more realistic assessments about the likelihood of candidate success.
• Adoption of adaptive clinical trial designs will accelerate, particularly in earlier clinical phases, as cross-functional teams within sponsor companies look to increase program success rates while lowering costs and disruptions from protocol amendments.
• The U.S. Food and Drug Administration will foster greater use of patient-reported outcomes to support labeling claims in drug applications and make greater use of social media and the Internet to communicate with patients, caregivers, and patient advocates.
• Sustaining the recent pace of investments in new biotech companies will be a major challenge in 2014, spurring further development of alternative financing approaches, e.g., industry based venture capital groups and patient support foundations.
• More approvals of co-developed companion diagnostics and therapeutics are likely, but diagnostics without evidence of positive impact on health outcomes will continue to face reimbursement challenges.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.